454 Life Sciences, a Roche company, is a biotechnology company based in Branford, Connecticut specializing in high-throughput DNA sequencing using a novel massively parallel sequencing-by-synthesis approach. 454 has experienced rapid growth since its acquisition by Roche Diagnostics and release of the GS20 sequencing machine in 2005, the first next-generation DNA sequencer on the market. With its high accuracy, low cost, and long reads, many rese...
more
454 Life Sciences, a Roche company, is a biotechnology company based in Branford, Connecticut specializing in high-throughput DNA sequencing using a novel massively parallel sequencing-by-synthesis approach. 454 has experienced rapid growth since its acquisition by Roche Diagnostics and release of the GS20 sequencing machine in 2005, the first next-generation DNA sequencer on the market. With its high accuracy, low cost, and long reads, many researchers have migrated away from traditional Sanger capillary sequencing instruments and toward the 454 Sequencing platform for a variety of genome projects.
In 2008, 454 Sequencing launched the GS FLX Titanium series reagents for use on the Genome Sequencer FLX instrument, with the ability to sequence 400-600 million base pairs per run with 400-500 base pair read lengths. Continued improvements to the GS FLX System include simplification of the sample preparation workflow, including emPCR automation, and even longer reads. The company plans to...
less
